AKT1 and acute myeloid leukemia: As shown in Figure 5, MK-2206 dose-dependently increased in vitro GO cytotoxicity in all 4 cell lines, with most marked effects noted in the GO-resistant TF-1 and KG-1 cell lines, suggesting that inhibition of PI3K/AKT survival signaling can sensitize otherwise resistant AML cells to GO-induced cytotoxicity.